Impact of Type of Treatment Center and Access to Care on Mortality and Survival for Skull Base Chordoma and Chondrosarcoma

Abstract

Introduction In adults with skull base chordoma or chondrosarcoma, the impact of treatment center and access to care have not been well described in regard to perioperative mortality and survival.

Methods A query of the National Cancer Database (NCDB) and review of 1,102 adults—488 with chordomas and 614 with chondrosarcomas—was performed. The Kaplan–Meier's product limit method and chi-square analysis, respectively, assessed overall survival and 30-day (30D) and 90-day (90D) mortalities.

Results For 925 patients who had surgery and available mortality data, the 30D and 90D mortality rates were 0.9 and 1.5%. Lower education level (p = 0.0185) and treatment at a nonacademic facility (p = 0.016) were associated with increased risk of 90-day mortality. Median follow-up was 52 months and analysis was dichotomized by histology. For those with skull base chordoma, patients from a larger metro size (p = 0.002), age below the median 52 years (p ≤ 0.001), and private insurance (<0.001) were associated with prolonged survival, whereas for skull base chondrosarcoma, the factors were treatment at an academic medical center (p = 0.001), high-volume center (p = 0.007), age below the median 52 years (p ≤ 0.001), higher income (p = 0.043), higher education (p = 0.017), and private insurance (p ≤ 0.001). Comparing high-, medium-, and low-volume centers, high-volume centers were most likely to be academic, deliver radiotherapy, escalate doses >70 Gy, and utilize proton radiotherapy consistent across both disease subsets.

Conclusion Higher educational attainment and treatment at an academic facility were associated with decreased 90D mortality for patients with skull base chordoma and chondrosarcoma. For those with skull base chordoma, larger metro size, younger age, and private insurance were associated with prolonged survival; for those with chondrosarcoma, it was treatment at a high-volume or academic medical center, younger age, higher income or education, and private insurance.

Keywords

skull base tumors - chordoma - chondrosarcoma

Publication History

Received: 09 April 2020

Accepted: 04 October 2020

Article published online:
09 March 2021

• References

• 1 Harsh GR. Chordomas and Chondrosarcomas of the Skull Base and Spine. 2nd ed.. San Diego, United States: Elsevier Science Publishing Co Inc; 2017
• 2 Holtzman AL, Rotondo RL, Rutenberg MS. et al. Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study. J Neurooncol 2019; 142 (03) 557-563
• 3 Mercado CE, Holtzman AL, Rotondo R, Rutenberg MS, Mendenhall WM. Proton therapy for skull base tumors: a review of clinical outcomes for chordomas and chondrosarcomas. Head Neck 2019; 41 (02) 536-541
• 4 Crockard HA, Steel T, Plowman N. et al. A multidisciplinary team approach to skull base chordomas. J Neurosurg 2001; 95 (02) 175-183
• 5 Leeman JE, Lee NY, Zhou Y. et al. Endoscopic resection followed by proton therapy with pencil beam scanning for skull base tumors. Laryngoscope 2019; 129 (06) 1313-1317
• 6 Bohman LE, Koch M, Bailey RL, Alonso-Basanta M, Lee JY. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis. World Neurosurg 2014; 82 (05) 806-814
• 7 Li D, Weng JC, Zhang GJ. et al. Proposed treatment paradigm for intracranial chondrosarcomas based on multidisciplinary coordination. World Neurosurg 2018; 109: e517-e530
• 8 Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999; 175 (Suppl. 02) 57-63
• 9 Weber DC, Murray F, Combescure C. et al. Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy. Radiother Oncol 2018; 129 (03) 520-526
• 10 Feuvret L, Bracci S, Calugaru V. et al. Efficacy and safety of adjuvant proton therapy combined with surgery for chondrosarcoma of the skull base: a retrospective, population-based study. Int J Radiat Oncol Biol Phys 2016; 95 (01) 312-321
• 11 Palm RF, Oliver DE, Yang GQ, Abuodeh Y, Naghavi AO, Johnstone PAS. The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: an analysis of the National Cancer Database. Cancer 2019; 125 (04) 642-651
• 12 Birkmeyer JD, Siewers AE, Finlayson EV. et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346 (15) 1128-1137
• 13 Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349 (22) 2117-2127
• 14 Koshy M, Sher DJ, Spiotto M. et al. Association between hospital volume and receipt of treatment and survival in patients with glioblastoma. J Neurooncol 2017; 135 (03) 529-534
• 15 Hahn RA, Truman BI. Education improves public health and promotes health equity. Int J Health Serv 2015; 45 (04) 657-678
• 16 Koutourousiou M, Gardner PA, Tormenti MJ. et al. Endoscopic endonasal approach for resection of cranial base chordomas: outcomes and learning curve. Neurosurgery 2012; 71 (03) 614-624 , discussion 624–625
• 17 Indelicato DJ, Rotondo RL, Begosh-Mayne D. et al. A prospective outcomes study of proton therapy for chordomas and chondrosarcomas of the spine. Int J Radiat Oncol Biol Phys 2016; 95 (01) 297-303